Avenciguat (BI 685509): sGC activator | SSc
Phase 2
Indication: Systemic sclerosis (SSc)
US FDA Fast Track Designation
This compound is under investigation, further information will be available soon.
Phase 2
Indication: Systemic sclerosis (SSc)
US FDA Fast Track Designation
This compound is under investigation, further information will be available soon.